Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

By M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin and 10 more. Journal of Clinical Oncology, 2003

2,840 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/98b7aebdf14fe38993cb1ec6054b0d50745183d4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. William Pao
2. Jeremy N. Rich
3. Adi F. Gazdar
4. Vincent A. Miller
5. M. Kris
6. H. Shigematsu

In Pulmonary and Respiratory Medicine

1. William Pao
2. Adi F. Gazdar
3. B. Hughes
4. B. Chan
5. Vincent A. Miller
6. M. Kris
7. Gregory Riely

Citations in the corpus

• Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib (2006, background): “The mean duration of the initial response is about 3 to 7 months (7, 8).”
• Phase II trial of gefitinib in recurrent glioblastoma. (2004, background): “Skin toxicity and diarrhea have been shown to be related to systemic EGFR antagonism and sometimes correlated with treatment response in some trials [12], but patients with other cancer types have also responded to gefitinib in the absence of toxicity [13,29].”